Dr. Udit Verma on Regorafenib in Patients With mCRC

Udit Verma, MD
Published: Wednesday, Apr 13, 2016



Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

In the phase IIIB CONSIGN study, 2872 patients with mCRC who failed standard therapy were treated with regorafenib, which demonstrated a median progression-free survival of 2.7 months. This retrospective subgroup analysis sought to confirm previous findings as well as the safety profile of regorafenib. This study’s primary endpoint was safety, Verma adds.

The most common grade 3 adverse events were hand-foot skin reaction (16%), hypertension (15%), fatigue, and diarrhea. These findings were similar as to what was reported in the phase III CORRECT trial, Verma explains.



Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

In the phase IIIB CONSIGN study, 2872 patients with mCRC who failed standard therapy were treated with regorafenib, which demonstrated a median progression-free survival of 2.7 months. This retrospective subgroup analysis sought to confirm previous findings as well as the safety profile of regorafenib. This study’s primary endpoint was safety, Verma adds.

The most common grade 3 adverse events were hand-foot skin reaction (16%), hypertension (15%), fatigue, and diarrhea. These findings were similar as to what was reported in the phase III CORRECT trial, Verma explains.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x